Leadership: Page 2


  • Ayman AlAbdallah header
    Image attribution tooltip
    Permission granted by Mubadala Capital
    Image attribution tooltip
    Q&A

    In biotech’s new market normal, here’s what’s catching this investor’s eye

    A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.

    By July 25, 2024
  • Vice President Harris Holds Campaign Event In Kalamazoo, Michigan
    Image attribution tooltip
    Chris duMond via Getty Images
    Image attribution tooltip

    Where Kamala Harris stands on three key pharma issues

    The presumptive Democratic nominee has a long history of taking on pharma over drug prices and supporting women’s healthcare access.

    By July 24, 2024
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead’s CMO to depart next year

    Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.

    By Ned Pagliarulo • July 19, 2024
  • Dr. Jared Baeten, senior vice president of clinical development, virology therapeutic area head, Gilead
    Image attribution tooltip
    Permission granted by Gilead
    Image attribution tooltip

    Gilead eyes ‘ending the HIV epidemic’ via incremental progress

    With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.

    By July 18, 2024
  • Amylyx co-ceos
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline

    Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.

    By July 17, 2024
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer research chief Dolsten to step down, with company at a crossroads

    The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.

    By Ben Fidler • July 10, 2024
  • David Dodd, CEO, GeoVax
    Image attribution tooltip
    Permission granted by GeoVax
    Image attribution tooltip

    In the rapidly shrinking COVID market, this company still sees opportunity

    GeoVax is developing a next-gen COVID vaccine targeting a population that’s so far been elusive: immunocompromised patients.

    By Alexandra Pecci • July 3, 2024
  • Mehrdad Mobasher, chief medical officer, hematology, BeiGene
    Image attribution tooltip
    Permission granted by BeiGene
    Image attribution tooltip
    Q&A

    How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal

    BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.

    By July 2, 2024
  • Lovisa Afzelius, co-founder, CEO, Prologue Medicines
    Image attribution tooltip
    Permission granted by Prologue Medicines
    Image attribution tooltip
    Biotech Spotlight

    Protein power: a biotech mining viruses to fight disease

    Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.

    By Kelly Bilodeau • July 1, 2024
  • Faye Feller, executive vice president, chief medical officer, Geron
    Image attribution tooltip
    Permission granted by Geron
    Image attribution tooltip

    After 33 years, Geron’s first approval marks a turn in Nobel-winning science

    The decades-long story of how a first-in-class blood cancer treatment went from bench to bedside.

    By Alexandra Pecci • June 26, 2024
  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners

    With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth. 

    By June 24, 2024
  • Junk yard
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

    Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.

    By June 18, 2024
  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip
    Making Moves

    Regenxbio CEO to step down after 15 years

    Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

    By Ned Pagliarulo • June 13, 2024
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    As Big Pharma places bigger bets on ADCs, here’s where the field is headed next

    With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.

    By June 11, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Behind Big Pharma’s layoffs — is there an end in sight?

    A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

    By Kelly Bilodeau • June 10, 2024
  • gambling chips
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s R&D gamble: picking pipeline winners in a risky field

    How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

    By June 7, 2024
  • City of Hope Helford Clinical Research Hospital in Duarte, California
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

    Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

    By June 6, 2024
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

    Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

    By June 3, 2024
  • Medicine capsules on blue racing lines
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In an era of big patent losses, drug launches need years of runway

    Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

    By June 3, 2024
  • Dave Kappos, former director, U.S. PTO
    Image attribution tooltip
    Permission granted by Cravath, Swaine & Moore
    Image attribution tooltip

    As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’

    To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.

    By May 30, 2024
  • Robot arm DNA
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can robots break the cell therapy bottleneck?

    A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

    By May 29, 2024
  • Pascal Soriot, CEO, AstraZeneca
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets

    Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

    By May 23, 2024
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era

    Heather Dean discusses the company’s neuroscience pipeline in epilepsy and narcolepsy and moving from a mass market to a rare disease mentality.

    By Alexandra Pecci • May 21, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies

    Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said. 

    By May 20, 2024
  • Novartis CEO Vas Narasimham
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large

    Execs from J&J, Novartis, Novo Nordisk and AbbVie sound off on the Inflation Reduction Act, supply issues and launch preparations in a tricky environment.

    By May 16, 2024